The company predicts the combination can help patients lose about 25% of their body weight, more than approved drugs Wegovy ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Eli Lilly has received approval to start selling its weight loss drug, Mounjaro, in Hong Kong as early as the end of this ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Adults With Obesity More Likely to Ration Drugs to Save Money. Adults with obesity are more likely to ration their ...

The drugs whose labels were updated include Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro. The agency said, ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Conditions are getting a bit more challenging for the drugmaker.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...